Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Medical Oncology
•
Leukemia
•
MD Anderson
•
AML
•
AYA
•
AYA Tumor Board
If AYA patients with AML are MRD negative after 1 cycle of chemotherapy, and high risk for relapse, should they receive additional cycles of chemotherapy or proceed directly to transplant?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Does treating CLL reduce the risk of non-melanoma skin cancers?
What induction regimen would you consider for KMT2A-rearranged AML in a young patient with multiple medical co-morbidities who is ineligible for clinical trials?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
